

**INFORMATION PURSUANT TO SECTION 125 OF THE GERMAN STOCK  
CORPORATION ACT ("AktG"),  
ART. 4 PARA. 1, TABLE 3 OF THE ANNEX TO IMPLEMENTING REGULATION (EU)  
2018/1212 ("EU-IR")**

Type of Indication	Description
<b>A. Specification of the message</b>	
1. Unique identifier of the event	Extraordinary General Meeting of PharmaSGP Holding SE 2025 Formal specification according to EU-IR: <i>329dc894068ff011b54b9fa33c931e38</i>
2. Type of message	Convening of the Extraordinary General Meeting Formal specification according to EU-IR: <i>NEWM</i>
<b>B. Specification of the issuer</b>	
1. ISIN	DE000A2P4LJ5
2. Name of issuer	PharmaSGP Holding SE
<b>C. Specification of the Meeting</b>	
1. Date of the General Meeting	October 31, 2025 Formal specification according to EU-IR: <i>20251031</i>
2. Time of the General Meeting	10:00 a.m. CET Formal specification according to EU-IR: <i>09:00 UTC</i>
3. Type of the General Meeting	Extraordinary general meeting Formal specification according to EU-IR: <i>XMET</i>
4. Location of the General Meeting	Haus der Bayerischen Wirtschaft, Max-Joseph-Straße 5, 80333 Munich, Germany
5. Record Date	The record date is October 9, 2025, end of the day CEST Formal specification according to EU-IR: <i>20251009, 22:00 UTC</i>
6. Uniform Resource Locator (URL)	<a href="https://ir.pharmasgp.com/#Hauptversammlung">https://ir.pharmasgp.com/#Hauptversammlung</a>

<b>D. Participation in the general meeting – Voting by personal participation</b>	
1. Method of participation by shareholder	Personal attendance on site Formal specification according to EU-IR: <i>PH</i>
2. Issuer deadline for the notification of participation	Shareholder registration for the Extraordinary General Meeting until October 24, 2025, end of the day CEST; receipt decisive Formal specification according to EU-IR: <i>20251024, 22:00 UTC</i>
3. Issuer deadline for voting	Personal attendance on site is possible on October 31, 2025, from 10:00 a.m. CET (Formal specification according to EU-IR: <i>20251031, from 09:00 UTC</i> ).  Voting on site is possible until the end of the respective voting at the Extraordinary General Meeting, as announced by the chairman of the meeting.
<b>D. Participation in the general meeting – Exercising the right to vote by granting authority and issuing instructions to the proxies nominated by the Company</b>	
1. Method of participation by shareholder	Exercise of voting rights by granting power of attorney and issuing instructions to the proxies appointed by the Company Formal specification according to EU-IR: <i>PX</i>
2. Issuer deadline for the notification of participation	Shareholder registration for the Extraordinary General Meeting until October 24, 2025, end of the day CEST; receipt decisive Formal specification according to EU-IR: <i>20251024, 22:00 UTC</i>
3. Issuer deadline for voting	Granting, amending or revoking the power of attorney and instructions to the proxies appointed by the company  - which is made by post or e-mail or pursuant to section 67c AktG via SWIFT: until October 30, 2025, 6:00 p.m. CET, receipt decisive; Formal specification according to EU-IR: <i>20251030, 17:00 UTC</i>  - which takes place during the Extraordinary General Meeting: at the entrance and exit control to the Extraordinary General Meeting on the day of the Extraordinary General Meeting October 31, 2025, from 10:00 a.m. CET Formal specification according to EU-IR: <i>20251031, from 09:00 UTC</i> until the beginning of the respective voting, as announced by the chairman of the meeting

<b>D. Participation in the general meeting – Exercising the right to vote by proxy</b>	
1. Method of participation by shareholder	Granting of proxy to another authorised representative Formal specification according to EU-IR: <i>PX</i>
2. Issuer deadline for the notification of participation	Shareholder registration for the Extraordinary General Meeting until October 24, 2025, end of the day CEST; receipt decisive Formal specification according to EU-IR: <i>20251024, 22:00 UTC</i>
3. Issuer deadline for voting	Granting or revoking proxy by declaration to the Company or transmission of the proof of a proxy declared to the representative or its revocation, by mail or email or pursuant to section 67c AktG via SWIFT:  until October 30, 2025, 6:00 p.m. CET, receipt decisive; formal specification according to EU-IR: <i>20251030, 17:00 UTC</i> .  Otherwise, no deadline set by the issuer.
<b>E. Agenda – Agenda item 1</b>	
1. Unique identifier of the agenda item	1
2. Title of the agenda item	Resolution on the transfer of the shares of the other shareholders (minority shareholders) of PharmaSGP Holding SE to FUTRUE GmbH against granting of an adequate cash compensation pursuant to sections 327a et seq. AktG
3. Uniform Resource Locator (URL) of the materials	<a href="https://ir.pharmasgp.com/#Hauptversammlung">https://ir.pharmasgp.com/#Hauptversammlung</a>
4. Vote	Binding vote Formal specification according to EU-IR: <i>BV</i>
5. Alternative voting options	Vote in favour, Vote against, Abstention Formal specification according to EU-IR: <i>VF, VA, AB</i>
<b>F. Specification of the deadlines regarding the exercise of other shareholders rights – Additions to the agenda requested by a minority pursuant to section 122 para. 2 AktG</b>	
1. Object of deadline	Transmission of the request for additions to the agenda
2. Applicable issuer deadline	October 6, 2025, end of the day CEST Formal specification according to EU-IR: <i>20251006, 22:00 UTC</i>

<b>F. Specification of the deadlines regarding the exercise of other shareholders rights – Shareholders' counter motions pursuant to section 126 AktG</b>	
1. Object of deadline	Submission of counter motions in response to resolutions proposed on the agenda items
2. Applicable issuer deadline	October 16, 2025, end of the day CEST Formal specification according to EU-IR: <i>20251016, 22:00 UTC</i>
<b>F. Specification of the deadlines regarding the exercise of other shareholders rights – Shareholders' proposals for election pursuant to section 127 AktG</b>	
1. Object of deadline	Submission of proposals for election in respect of elections of candidates to the Supervisory Board and the appointment of the auditors
2. Applicable issuer deadline	October 16, 2025, end of the day CEST Formal specification according to EU-IR: <i>20251016, 22:00 UTC</i>  Please note that the present agenda – subject to a subsequent addition – does not include the election of Supervisory Board members or auditors
<b>F. Specification of the deadlines regarding the exercise of other shareholders rights – Right to information pursuant to Section 131 AktG</b>	
1. Object of deadline	Shareholders' right to information pursuant to Section 131 AktG
2. Applicable issuer deadline	On October 31, 2025, during the Extraordinary General Meeting until the time determined by the chairman of the meeting Formal specification according to EU-IR: <i>20251031; during the general meeting until the time determined by the chairman of the meeting</i>  The request pursuant to Section 131 para. 5 sentence 1 AktG can be made until the end of the Extraordinary General Meeting.
<b>F. Specification of the deadlines regarding the exercise of other shareholders rights – Shareholders' rights to speak and to submit motions</b>	
1. Object of deadline	Shareholders' rights to speak and to submit motions at the Extraordinary General Meeting
2. Applicable issuer deadline	On October 31, 2025, during the Extraordinary General Meeting until the time determined by the chairman of the meeting Formal specification according to EU-IR: <i>20251031; during the general meeting until the time determined by the chairman of the meeting</i>

<b>F. Specification of the deadlines regarding the exercise of other shareholders rights – Objection to resolutions of the Extraordinary General Meeting</b>	
1. Object of deadline	Objection to resolutions of the Extraordinary General Meeting
2. Applicable issuer deadline	On October 31, 2025, from the opening of the Extraordinary General Meeting until its closing by the chairman of the Meeting Formal specification according to EU-IR: <i>20251031; from the opening of the Extraordinary General Meeting until its closing by the chairman of the Meeting</i>

### **Further information**

Further information can be found, in particular, in the notice of the Extraordinary General Meeting, which is available on the company's website at <https://ir.pharmasgp.com/#Hauptversammlung>.